Pharmaceutical use

A method for treating a sex-hormone dependent disease in a subject diagnosed with the sex-hormone-dependent disease, wherein said sex-hormone disease is estrogen-receptor positive breast cancer, the method comprising topically administering to the subject a treatment effective amount of a pharmaceutical composition, consisting of:

• a steroidal aromatase-inactivator, wherein the steroidal aromatase-inactivator is 4-hydroxyandrostenedione, exemestane, or 4-acetoxyandrostenedione, wherein the steroidal aromatase-inactivator is from 1 wt. % to 3 wt. % of the total composition;
• an antioxidant, wherein the antioxidant is α-lipoic acid, wherein the antioxidant is from 0.5 wt.-% to 2 wt. % of the total composition;
• hyaluronic acid, wherein the hyaluronic acid is from 0.2 wt.-% to 0.3 wt. % of the total composition;
• optionally, one or more carriers, wherein the one or more carriers are selected from the group consisting of glycerol monostearate, cetyl alcohol, medium chain triglycerides, white petrolatum, polyethylene glycol-20-glycerolmonostearate, propylene glycol, and purified water;
• and
• optionally, one or more additional additives selected from the group consisting of amino acids, mineral nutrients (trace elements) and polysaccharides;
• wherein said topical pharmaceutical composition is formulated as a cream, a gel, an ointment or an emulsion.

A method for treating a sex-hormone dependent disease in a subject diagnosed with the sex-hormone dependent disease, wherein said sex-hormone dependent disease is estrogen-receptor positive breast cancer, the method comprising topically administering to the subject a treatment effective amount of a pharmaceutical medication consisting essentially of two active ingredients, wherein the two active ingredients are a steroidal aromatase-inhibitor and an antioxidant that is different from the aromatase-inhibitor;

• wherein the steroidal aromatase inhibitor is a steroidal aromatase inactivator selected from the group consisting of 4-hydroxyandrostenedione, exemestane, 4-acetoxyandrostenedione, 5-alpha-androst-3-ene-17-one, and 3-alpha,4-alpha-epoxy-5-alpha-androstane-17-one;
• wherein the antioxidant is alpha-lipoic acid;
• wherein the pharmaceutical medication comprises 0.05-5 wt.-% of antioxidant and 0.1-5 wt.-% steroidal aromatase inhibitor;
• and
• wherein the treatment is continued or resumed after an initial treatment of breast cancer.